Tracy R Glass1, Jonathan A C Sterne, Marie-Paule Schneider, Sabina De Geest, Dunja Nicca, Hansjakob Furrer, Huldrych F Günthard, Enos Bernasconi, Alexandra Calmy, Martin Rickenbach, Manuel Battegay, Heiner C Bucher. 1. aBasel Institute for Clinical Epidemiology and Biostatistics, University Hospital Basel bSwiss Tropical and Public Health Institute cUniversity of Basel, Basel, Switzerland dDepartment of Social Medicine, University of Bristol, Bristol, UK eCommunity pharmacy, Department of Ambulatory Care and Community Medicine, University of Lausanne fCommunity pharmacy, School of Pharmaceutical Sciences, University of Geneva, University of Lausanne, Lausanne gInstitute of Nursing Science, University of Basel, Basel hDivision of Infectious Diseases, Kantonsspital St. Gallen, St. Gallen iDepartment of Infectious Diseases, Bern University Hospital and University of Bern, Bern jDivision of Infectious Diseases and Hospital Epidemiology University Hospital Zurich and University of Zurich, Zurich kDivision of Infectious Diseases, Ospedale Civico Lugano, Lugano lDivision of Infectious Diseases, University Hospital Geneva, Geneva mSwiss HIV Cohort Data Center, University Institute of Social and Preventive Medicine Lausanne, Lausanne nDivision of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, Basel, Switzerland.
Abstract
OBJECTIVE: To determine the effect of nonadherence to antiretroviral therapy (ART) on virologic failure and mortality in naive individuals starting ART. DESIGN: Prospective observational cohort study. METHODS: Eligible individuals enrolled in the Swiss HIV Cohort Study, started ART between 2003 and 2012, and provided adherence data on at least one biannual clinical visit. Adherence was defined as missed doses (none, one, two, or more than two) and percentage adherence (>95, 90-95, and <90) in the previous 4 weeks. Inverse probability weighting of marginal structural models was used to estimate the effect of nonadherence on viral failure (HIV-1 viral load >500 copies/ml) and mortality. RESULTS: Of 3150 individuals followed for a median 4.7 years, 480 (15.2%) experienced viral failure and 104 (3.3%) died, 1155 (36.6%) reported missing one dose, 414 (13.1%) two doses and, 333 (10.6%) more than two doses of ART. The risk of viral failure increased with each missed dose (one dose: hazard ratio [HR] 1.15, 95% confidence interval 0.79-1.67; two doses: 2.15, 1.31-3.53; more than two doses: 5.21, 2.96-9.18). The risk of death increased with more than two missed doses (HR 4.87, 2.21-10.73). Missing one to two doses of ART increased the risk of viral failure in those starting once-daily (HR 1.67, 1.11-2.50) compared with those starting twice-daily regimens (HR 0.99, 0.64-1.54, interaction P = 0.09). Consistent results were found for percentage adherence. CONCLUSION: Self-report of two or more missed doses of ART is associated with an increased risk of both viral failure and death. A simple adherence question helps identify patients at risk for negative clinical outcomes and offers opportunities for intervention.
OBJECTIVE: To determine the effect of nonadherence to antiretroviral therapy (ART) on virologic failure and mortality in naive individuals starting ART. DESIGN: Prospective observational cohort study. METHODS: Eligible individuals enrolled in the Swiss HIV Cohort Study, started ART between 2003 and 2012, and provided adherence data on at least one biannual clinical visit. Adherence was defined as missed doses (none, one, two, or more than two) and percentage adherence (>95, 90-95, and <90) in the previous 4 weeks. Inverse probability weighting of marginal structural models was used to estimate the effect of nonadherence on viral failure (HIV-1 viral load >500 copies/ml) and mortality. RESULTS: Of 3150 individuals followed for a median 4.7 years, 480 (15.2%) experienced viral failure and 104 (3.3%) died, 1155 (36.6%) reported missing one dose, 414 (13.1%) two doses and, 333 (10.6%) more than two doses of ART. The risk of viral failure increased with each missed dose (one dose: hazard ratio [HR] 1.15, 95% confidence interval 0.79-1.67; two doses: 2.15, 1.31-3.53; more than two doses: 5.21, 2.96-9.18). The risk of death increased with more than two missed doses (HR 4.87, 2.21-10.73). Missing one to two doses of ART increased the risk of viral failure in those starting once-daily (HR 1.67, 1.11-2.50) compared with those starting twice-daily regimens (HR 0.99, 0.64-1.54, interaction P = 0.09). Consistent results were found for percentage adherence. CONCLUSION: Self-report of two or more missed doses of ART is associated with an increased risk of both viral failure and death. A simple adherence question helps identify patients at risk for negative clinical outcomes and offers opportunities for intervention.
Authors: David P Sheppard; Erica Weber; Kaitlin B Casaletto; Gunes Avci; Steven Paul Woods Journal: J Assoc Nurses AIDS Care Date: 2016-04-06 Impact factor: 1.354
Authors: Awachana Jiamsakul; Azar Kariminia; Keri N Althoff; Carina Cesar; Claudia P Cortes; Mary-Ann Davies; Viet Chau Do; Brian Eley; John Gill; Nagalingeswaran Kumarasamy; Daisy Maria Machado; Richard Moore; Hans Prozesky; Elizabeth Zaniewski; Matthew Law Journal: J Acquir Immune Defic Syndr Date: 2017-11-01 Impact factor: 3.731
Authors: Huldrych F Günthard; Michael S Saag; Constance A Benson; Carlos del Rio; Joseph J Eron; Joel E Gallant; Jennifer F Hoy; Michael J Mugavero; Paul E Sax; Melanie A Thompson; Rajesh T Gandhi; Raphael J Landovitz; Davey M Smith; Donna M Jacobsen; Paul A Volberding Journal: JAMA Date: 2016-07-12 Impact factor: 56.272
Authors: Kenneth H Mayer; Steven A Safren; Steven A Elsesser; Christina Psaros; Jake P Tinsley; Mark Marzinke; William Clarke; Craig Hendrix; S Wade Taylor; Jessica Haberer; Matthew J Mimiaga Journal: AIDS Behav Date: 2017-05
Authors: Brandon A Knettel; Lisa Wanda; Ismail Amiri; John Myers; Kimberly M Fernandez; Charles Muiruri; Melissa H Watt; Blandina T Mmbaga; Michael V Relf Journal: AIDS Patient Care STDS Date: 2021-08 Impact factor: 5.944
Authors: Sara Lodi; Huldrych F Günthard; David Dunn; Federico Garcia; Roger Logan; Sophie Jose; Heiner C Bucher; Alexandra U Scherrer; Marie-Paule Schneider; Matthias Egger; Tracy R Glass; Peter Reiss; Ard van Sighem; T Sonia Boender; Andrew N Phillips; Kholoud Porter; David Hawkins; Santiago Moreno; Susana Monge; Dimitrios Paraskevis; Metallidis Simeon; Georgia Vourli; Caroline Sabin; Miguel A Hernán Journal: AIDS Date: 2018-01-28 Impact factor: 4.177